Illustrative image.
Trodelvy
Sacituzumab Govitecan
$2210.00
200mg · 1
BrandBranded medicine· By Gilead Sciences
Choose a pack
- Selected pack
Packs in this delivery
Test mode: no payment is taken. View cart
Prescription required
Upload your prescription after ordering, or send it to our pharmacy team. We dispense only against a valid prescription.
FDA boxed warningNeutropenia and diarrhea
TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay.
TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses.
About Trodelvy
Overview
Trodelvy (sacituzumab govitecan) is an antibody linked to a cancer-killing medicine. It is used in adults with triple-negative breast cancer that is locally advanced and cannot be removed surgically, or has spread elsewhere, either as first-line treatment in certain patients or after previous systemic treatments. It also treats adults with hormone receptor-positive, HER2-negative breast cancer at these stages after endocrine-based therapy and at least two additional systemic therapies for metastatic disease. The antibody targets a protein called Trop-2 on cancer cells and releases SN-38, a substance that damages their DNA and leads to cell death.
What it treats
- Triple-negative breast cancer in adults that is locally advanced and cannot be surgically removed, or has spread to other parts of the body: - As first-line treatment on its own when PD-1 or PD-L1 inhibitor-based therapy is not suitable. - As first-line treatment with pembrolizumab, or with pembrolizumab and berahyaluronidase alfa-pmph, when the tumour expresses PD-L1 (CPS ≥10), confirmed by an FDA-authorized test. - After at least two previous systemic therapies, including at least one for metastatic disease. - Hormone receptor-positive, HER2-negative breast cancer in adults that is locally advanced and cannot be surgically removed, or has spread to other parts of the body, after endocrine-based therapy and at least two additional systemic therapies for metastatic disease.
Safety information
Side effects
Common side effects of Trodelvy include nausea, diarrhea, tiredness, hair loss, constipation, vomiting and abdominal pain. Reduced appetite is also common when Trodelvy is used alone. Rash and headache are also common when it is used with pembrolizumab. Common blood test changes include reduced white blood cells, including neutrophils and lymphocytes; reduced hemoglobin; low albumin and potassium; increased blood glucose; and increased levels of certain liver enzymes. When used alone, Trodelvy can also cause reduced magnesium and reduced creatinine clearance, a measure of kidney function. Additional blood test changes with pembrolizumab include increased eosinophils, a type of white blood cell, and increased lactate dehydrogenase. Serious risks include low neutrophil counts, including low counts with fever, diarrhea, severe nausea or vomiting, and allergic or infusion-related reactions. Contact your doctor promptly about severe diarrhea, nausea or vomiting, or fever associated with low neutrophil counts. Seek urgent medical help for a severe allergic or infusion-related reaction, which can be life-threatening. Severe or life-threatening reactions require permanent discontinuation of Trodelvy by the treating team. People with certain inherited changes affecting the UGT1A1 enzyme have a higher risk of low neutrophil counts, low neutrophil counts with fever, and anemia. Trodelvy can harm an unborn baby. Effective contraception is needed during treatment.
FDA boxed warning
Neutropenia and diarrhea
TRODELVY can cause severe, life-threatening, or fatal neutropenia. Withhold TRODELVY for absolute neutrophil count below 1500/mm 3 or neutropenic fever. Monitor blood cell counts periodically during treatment. Primary prophylaxis with G-CSF is recommended for all patients at increased risk of febrile neutropenia. Initiate anti-infective treatment in patients with febrile neutropenia without delay.
TRODELVY can cause severe diarrhea. Monitor patients with diarrhea and give fluid and electrolytes as needed. At the onset of diarrhea, evaluate for infectious causes and, if negative, promptly initiate loperamide. If severe diarrhea occurs, withhold TRODELVY until resolved to ≤ Grade 1 and reduce subsequent doses.
A boxed warning is the strongest warning the US Food and Drug Administration requires on a medicine label. Text is taken from the official label, with internal section references removed.
When to call your doctor
If symptoms are severe or getting worse quickly, seek emergency care rather than waiting.
Before taking this medicine
Do not use Trodelvy if you have previously had a severe allergic reaction to it. Trodelvy can cause severe allergic reactions, including anaphylaxis. Patients must be monitored for infusion-related reactions, and treatment must be permanently stopped if a severe or life-threatening reaction occurs. Preventive treatment for nausea and vomiting is needed. Treatment may need to be withheld if severe nausea or vomiting is present when treatment is due. People with two copies of the UGT1A1*28 gene variant have a higher risk of low neutrophil counts, low neutrophil counts with fever, and anaemia after starting treatment. Trodelvy can harm an unborn baby. Use effective contraception during treatment. Do not breastfeed while receiving Trodelvy.
Interactions
Avoid using Trodelvy with medicines that inhibit or induce the enzyme UGT1A1. Ask your doctor to check whether any medicines you take fall into these groups.
Using Trodelvy
Dosing
Dosing is set by your prescriber. Each health care professional may prescribe medication differently according to a patient's medical history and condition, so follow the directions on your prescription label and speak to your doctor or pharmacist before changing anything.
Storage
Store in the original carton below 25°C, protected from light, unless the pack states refrigeration. Do not freeze. Keep all medicines out of the sight and reach of children.
Clinical information on this page is summarised from the US FDA label TRODELVY (SACITUZUMAB GOVITECAN) POWDER, FOR SOLUTION [GILEAD SCIENCES, INC.] (DailyMed, retrieved 19 September 2026).
Reviews
No reviews yet. Mail Order Drugs opened recently, and we publish reviews only from verified customers of this site, so this space stays empty until real ones arrive.
- Every prescription order is checked by a licensed pharmacist before dispensing.
- Payment pages are encrypted and card details never reach our servers.
- We ship internationally, with cold-chain packing where a medicine needs it.
Related medicines
Busulfex
Busulfan
By Otsuka America Pharmaceutical
Vial · from 1 per pack
Also for cancer treatment
Brand $551.00
Brukinsa
Zanubrutinib
By BeiGene
Capsules · from 120 per pack
Also for cancer treatment
Brand $10,520.00
Temodar
Temozolomide
By Orion
Tablets · from 5 per pack
Also for cancer treatment
Brand from $46.00
Ojjaara
Momelotinib (momelotinib Dihydrochloride)
By GlaxoSmithKline
Tablets · from 30 per pack
Also for cancer treatment
Brand $12,585.00